Iberdomide

Iberdomide (CC-220) is an experimental thalidomide analog^[1] that works as an cereblon E3 ligase modulator; it has a higher binding affinity than lenalidomide or pomalidomide. It is developed by Bristol Myers Squibb for various cancers^{[2][3][4][5][6][7][8]} and was also tested in people with lupus.^[9]

CAS Number

• 1323403-33-3

PubChem CID

• 67335295

IUPHAR/BPS

• 9618

DrugBank

• DB12101

Quick facts Identifiers, CAS Number ...

Iberdomide

Identifiers
IUPAC name (3S)-3-[7-({4-[(morpholin-4-yl)methyl]phenyl}methoxy)-3-oxo-1H-isoindol-2-yl]piperidine-2,6-dione
CAS Number	1323403-33-3
PubChem CID	67335295
IUPHAR/BPS	9618
DrugBank	DB12101
ChemSpider	52085251
UNII	8V66F27X44
KEGG	D11134
ChEMBL	ChEMBL3989927
Chemical and physical data
Formula	C25H27N3O5
Molar mass	449.507 g·mol−1
3D model (JSmol)	Interactive image
SMILES O=C1CC[C@H](N2Cc3c(OCc4ccc(CN5CCOCC5)cc4)cccc3C2=O)C(=O)N1
InChI InChI=1S/C25H27N3O5/c29-23-9-8-21(24(30)26-23)28-15-20-19(25(28)31)2-1-3-22(20)33-16-18-6-4-17(5-7-18)14-27-10-12-32-13-11-27/h1-7,21H,8-16H2,(H,26,29,30)/t21-/m0/s1 Key:IXZOHGPZAQLIBH-NRFANRHFSA-N

Close

Iberdomide has been tested in combination with Bi-specific T-cell engagers in the B-Cell Non-Hodgkin Lymphoma setting,^[10] but has been dropped in favor of golcadomide (CC-99282).